SIRT is better tolerated than sorafenib, but doesn’t increase overall survival in HCC
April 22, 2017, Amsterdam, The Netherlands: Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months...